摘要
背景:20世纪20年代首次考虑使用吖啶作为抗癌剂。此后,大量的吖啶类药物已经作为抗肿瘤剂进行了测试,包括吖啶发色团上含有硫的化合物。在这篇综述中,我们将讨论最近的研究,这些研究调查了这类吖啶衍生物的抗癌活性。 方法:我们将自己长达十年的研究结果以及现有研究文献的结果提交给含硫吖啶衍生物的抗癌活性。这些化合物表现出特定的肿瘤细胞杀伤特性的证据表明使用这种分子作为抗癌治疗剂的可能性。 结果:在过去的十年中,通过修改吖啶核上取代基的位置和性质开发了许多吖啶类似物。在本文中,我们发表了关于含硫吖啶衍生物(吖啶硫脲,吖啶噻唑烷/噻唑烷酮和吖啶缩氨基硫脲/氨基硫脲)的抗癌活性的结果。在癌症化疗中,药物的机理是复杂的,尽管对吖啶的抗癌活性的研究产生了令人兴奋的结果。 结论:在这篇综述中,我们总结了最近有关含硫吖啶衍生物抗癌活性的文献。大量公开的数据表明这些化合物对选定的癌细胞系显示出有希望的抗癌活性。所获得的结果可以有助于新药剂的开发。
关键词: 临床前研究,癌细胞系,吖啶衍生物,硫,硫脲,噻唑烷酮。
Current Medicinal Chemistry
Title:Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines
Volume: 25 Issue: 17
关键词: 临床前研究,癌细胞系,吖啶衍生物,硫,硫脲,噻唑烷酮。
摘要: Background: The possible use of acridines as anticancer agents was first considered in the 1920´s. Since then, a large number of acridine drugs have been tested as antitumour agents, including compounds containing sulphur on the acridine chromophore. In this review, we will discuss recent studies which have investigated the anticancer activity of this class of acridine derivatives.
Methods: We present the results both of our own decade-long research and also of existing research literature into the anticancer activity of acridine derivatives containing sulphur. The evidence of specific tumor-cell killing properties displayed by these compounds suggest the potential of using such molecules as anticancer therapeutics.
Results: During the last decade, a number of acridine analogs have been developed by modifying the position and the nature of the substituent on the acridine core. In this paper, we published results on the anticancer activity of acridine derivatives containing sulfur (acridine thioureas, acridine thiazolidine/thiazoidinone, and acridine thiosemicarbazones/ thiosemicarbazides). In cancer chemotherapy, the mechanism of the drugs is complex, although the study of the anticancer activity of acridines has yielded exciting results.
Conclusion: In this review we have summarized recent literature on the anticancer activity of acridine derivatives containing sulfur. A considerable amount of published data suggests that these compounds exhibit promising anticancer activity against selected cancer cell lines. The obtained results can be helpful in the development of new pharmaceutical agents.
Export Options
About this article
Cite this article as:
Sulfur Containing Acridine Derivatives in Preclinical Studies with Cancer Cell Lines, Current Medicinal Chemistry 2018; 25 (17) . https://dx.doi.org/10.2174/0929867324666170414165019
DOI https://dx.doi.org/10.2174/0929867324666170414165019 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fluorine-18 Labeled Amino Acids for Oncologic Imaging with Positron Emission Tomography
Current Topics in Medicinal Chemistry Palliative Care in High and Low Resource Countries
Current Pediatric Reviews Reactive Oxygen Species in Cancer Biology and Anticancer Therapy
Current Medicinal Chemistry Lycopene: A Review of Its Potential as an Anticancer Agent
Current Medicinal Chemistry - Anti-Cancer Agents Metabolite Quantification in Tumours by Magnetic Resonance Spectroscopy: Objectives, Results and Perspectives
Current Medical Imaging Cetuximab, A Chimeric Anti-Epidermal Growth Factor Receptor Monoclonal Antibody, in Colorectal Cancer Treatment
Current Cancer Therapy Reviews Glycerophospholipid Synthesis as a Novel Drug Target Against Cancer
Current Molecular Pharmacology Anticancer Mammalian Target of Rapamycin (mTOR) Signaling Pathway Inhibitors: Current Status, Challenges and Future Prospects in Management of Epilepsy
CNS & Neurological Disorders - Drug Targets Hypoxia and the Malignant Glioma Microenvironment: Regulation and Implications for Therapy
Current Molecular Pharmacology Overcoming the Blood-Brain Barrier for Chemotherapy: Limitations, Challenges and Rising Problems
Anti-Cancer Agents in Medicinal Chemistry Application of Mesenchymal Stem Cells in Melanoma: A Potential Therapeutic Strategy for Delivery of Targeted Agents
Current Medicinal Chemistry Patent Selections
Recent Patents on CNS Drug Discovery (Discontinued) Pharmacological Modulation of Nitric Oxide Release: New Pharmacological Perspectives, Potential Benefits and Risks
Current Medicinal Chemistry The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Current Medicinal Chemistry Novel Agents Aiming at Specific Molecular Targets Increase Chemosensitivity and Overcome Chemoresistance in Hematopoietic Malignancies
Current Pharmaceutical Design TRIM65 in White Matter Lesions, Innate Immunity, and Tumor
Current Molecular Pharmacology The Heat Shock Protein 90 Chaperone Complex: An Evolving Therapeutic Target
Current Cancer Drug Targets Wnt/beta-Catenin Signaling and Small Molecule Inhibitors
Current Pharmaceutical Design ATP Citrate Lyase (ACLY): A Promising Target for Cancer Prevention and Treatment
Current Drug Targets Receptor-Specific Peptides for Targeting of Liposomal, Polymeric, and Dendrimeric Nanoparticles in Cancer Diagnosis and Therapy
Current Molecular Imaging (Discontinued)